Skip to main content

Metastatic Lung Non-Small Cell Carcinoma clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for
  • [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy

    open to eligible people ages 18 years and up

    This trial studies how well [18F]-AraG works in detecting T-cell activation in patients with non-small cell lung cancer that has spread to other places in the body (advanced), who are undergoing PD-1/PD-L1-directed therapy. [18F]-AraG is a "radiotracer" which attaches to immune cells directed at the cancer and shines a light that can be seen using a special camera, called a "positron emission tomography" or "PET" scanner. [18F]-AraG may improve the ability to detect a response of the cancer in the body to immunotherapy.

    Sacramento, California

  • Testing the Anti Cancer Drugs Telaglenastat and Sapanisertib in Advanced Lung Cancer

    open to eligible people ages 18 years and up

    This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Sacramento, California and other locations

Last updated: